Suppr超能文献

先天免疫与 SARS-CoV-2 感染结局中的干扰素。

Innate immunity and interferon in SARS-CoV-2 infection outcome.

机构信息

Department of Immunology and Center for Innate Immunity and Immune Disease, University of Washington, 750 Republican St., Seattle, WA 98109, USA.

Department of Immunology and Center for Innate Immunity and Immune Disease, University of Washington, 750 Republican St., Seattle, WA 98109, USA.

出版信息

Immunity. 2023 Jul 11;56(7):1443-1450. doi: 10.1016/j.immuni.2023.06.018.

Abstract

Innate immunity and the actions of type I and III interferons (IFNs) are essential for protection from SARS-CoV-2 and COVID-19. Each is induced in response to infection and serves to restrict viral replication and spread while directing the polarization and modulation of the adaptive immune response. Owing to the distribution of their specific receptors, type I and III IFNs, respectively, impart systemic and local actions. Therapeutic IFN has been administered to combat COVID-19 but with differential outcomes when given early or late in infection. In this perspective, we sort out the role of innate immunity and complex actions of IFNs in the context of SARS-CoV-2 infection and COVID-19. We conclude that IFNs are a beneficial component of innate immunity that has mediated natural clearance of infection in over 700 million people. Therapeutic induction of innate immunity and use of IFN should be featured in strategies to treat acute SARS-CoV-2 infection in people at risk for severe COVID-19.

摘要

先天免疫和 I 型和 III 型干扰素(IFN)的作用对于预防 SARS-CoV-2 和 COVID-19 至关重要。每种干扰素都是在感染后诱导产生的,有助于限制病毒复制和传播,同时指导适应性免疫反应的极化和调节。由于其特定受体的分布,I 型和 III 型 IFN 分别具有全身和局部作用。IFN 已被用于治疗 COVID-19,但在感染早期或晚期使用时效果不同。在这种情况下,我们梳理了先天免疫和 IFN 的复杂作用在 SARS-CoV-2 感染和 COVID-19 中的作用。我们的结论是,IFN 是先天免疫的有益组成部分,它介导了超过 7 亿人对感染的自然清除。在治疗有发生严重 COVID-19 风险的人群的急性 SARS-CoV-2 感染时,应将先天免疫的治疗性诱导和 IFN 的使用作为策略的重要组成部分。

相似文献

1
Innate immunity and interferon in SARS-CoV-2 infection outcome.
Immunity. 2023 Jul 11;56(7):1443-1450. doi: 10.1016/j.immuni.2023.06.018.
4
SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Int J Mol Sci. 2023 May 27;24(11):9353. doi: 10.3390/ijms24119353.
7
Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
J Virol. 2022 Apr 13;96(7):e0170521. doi: 10.1128/jvi.01705-21. Epub 2022 Mar 9.
8
The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies.
Mol Ther. 2022 May 4;30(5):1869-1884. doi: 10.1016/j.ymthe.2022.02.014. Epub 2022 Feb 14.
9
Differential roles of interferons in innate responses to mucosal viral infections.
Trends Immunol. 2021 Nov;42(11):1009-1023. doi: 10.1016/j.it.2021.09.003. Epub 2021 Oct 7.

引用本文的文献

3
Viperin: A Multifunctional Protein in Antiviral Immunity and Disease Pathogenesis.
Pathogens. 2025 May 21;14(5):510. doi: 10.3390/pathogens14050510.
4
IFIT3: a crucial mediator in innate immunity and tumor progression with therapeutic implications.
Front Immunol. 2025 Feb 24;16:1515718. doi: 10.3389/fimmu.2025.1515718. eCollection 2025.
6
Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice.
J Virol. 2025 Mar 18;99(3):e0141324. doi: 10.1128/jvi.01413-24. Epub 2025 Feb 4.
7
Cellular RNA interacts with MAVS to promote antiviral signaling.
Science. 2024 Dec 20;386(6728):eadl0429. doi: 10.1126/science.adl0429.
8
Targeting viral suppressor of RNAi confers anti-coronaviral activity.
Mol Ther. 2025 Jan 8;33(1):201-214. doi: 10.1016/j.ymthe.2024.12.009. Epub 2024 Dec 10.
9
TNF-α exacerbates SARS-CoV-2 infection by stimulating CXCL1 production from macrophages.
PLoS Pathog. 2024 Dec 9;20(12):e1012776. doi: 10.1371/journal.ppat.1012776. eCollection 2024 Dec.
10
Multiple mechanisms enable broad-spectrum activity of the root extract EPs 7630 against acute respiratory tract infections.
Front Pharmacol. 2024 Oct 14;15:1455870. doi: 10.3389/fphar.2024.1455870. eCollection 2024.

本文引用的文献

1
A global analysis of the effectiveness of policy responses to COVID-19.
Sci Rep. 2023 Apr 6;13(1):5629. doi: 10.1038/s41598-023-31709-2.
4
Interferon therapy and its association with depressive disorders - A review.
Front Immunol. 2023 Feb 22;14:1048592. doi: 10.3389/fimmu.2023.1048592. eCollection 2023.
5
Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice.
EMBO Rep. 2023 Apr 5;24(4):e56660. doi: 10.15252/embr.202256660. Epub 2023 Mar 7.
7
Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.
Vaccines (Basel). 2023 Feb 10;11(2):408. doi: 10.3390/vaccines11020408.
9
Innate sensing and cellular metabolism: role in fine tuning antiviral immune responses.
J Leukoc Biol. 2023 Feb 1;113(2):164-190. doi: 10.1093/jleuko/qiac011.
10
Early Treatment with Pegylated Interferon Lambda for Covid-19.
N Engl J Med. 2023 Feb 9;388(6):518-528. doi: 10.1056/NEJMoa2209760.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验